Kim JH - Search Results

1

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ. Sun JM, et al. Among authors: kim st, kim jh. J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. J Cancer Res Clin Oncol. 2011. PMID: 20552223

2

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Sun JM, et al. Among authors: kim jh. J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. J Thorac Oncol. 2010. PMID: 20195170 Free article.

3

Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.

Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS. Ahn HK, et al. Among authors: kim sj, kim ws, kim jh, kim k. Int J Hematol. 2010 Apr;91(3):456-63. doi: 10.1007/s12185-010-0536-6. Epub 2010 Mar 3. Int J Hematol. 2010. PMID: 20198460

4

Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. Yun J, et al. Among authors: kim st, kim km, kim ja, kim jh. Cancer Res Treat. 2010 Jun;42(2):101-6. doi: 10.4143/crt.2010.42.2.101. Epub 2010 Jun 30. Cancer Res Treat. 2010. PMID: 20622964 Free PMC article.

5

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY. Baek KK, et al. Among authors: kim jh. Oncology. 2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24. Oncology. 2011. PMID: 21701230

6

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Oh SY, Lee S, Huh SJ, Lee J, Kim ST, Park SH, Lim HY, Kang WK, Kang BW, Kim JG, Lee HJ, Kim JH, Kang JH, Kim H. Oh SY, et al. Among authors: kim st, kim h, kim jg, kim jh. Cancer Chemother Pharmacol. 2019 Mar;83(3):501-508. doi: 10.1007/s00280-018-3753-y. Epub 2018 Dec 8. Cancer Chemother Pharmacol. 2019. PMID: 30535535

7

Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study.

Won YW, Chun HS, Seo M, Kim RB, Kim JH, Kang JH. Won YW, et al. Among authors: kim rb, kim jh. J Pain Symptom Manage. 2019 Jul;58(1):65-71. doi: 10.1016/j.jpainsymman.2019.04.019. Epub 2019 Apr 23. J Pain Symptom Manage. 2019. PMID: 31026509 Free article.

8

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.

Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. Yoon SE, et al. Among authors: kim st, kim jh. J Cancer. 2019 Jun 2;10(14):3140-3144. doi: 10.7150/jca.30355. eCollection 2019. J Cancer. 2019. PMID: 31289584 Free PMC article.

9

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK. Lee J, et al. Among authors: kim yh, kim jj, kim nkd, kim st, kim km, kim s, kim ys, kim j, kim y, kim k, kim jh. Cancer Discov. 2019 Oct;9(10):1388-1405. doi: 10.1158/2159-8290.CD-19-0442. Epub 2019 Jul 17. Cancer Discov. 2019. PMID: 31315834

10

Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial.

Kim R, Ji JH, Kim JH, Hong JY, Lim HY, Kang WK, Lee J, Kim ST. Kim R, et al. Among authors: kim st, kim jh. J Cancer. 2022 Jan 9;13(4):1097-1102. doi: 10.7150/jca.67050. eCollection 2022. J Cancer. 2022. PMID: 35281856 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32,081 results

Search Page

Filters